"[14D6EF7FB664]" . "How we indicate oral antidiabetics today (from metformin to gliptins and gliflozins)"@en . "60" . . "Diabetes mellitus 2. typu l\u00E9\u010D\u00EDme dnes postupn\u00FDm p\u0159id\u00E1v\u00E1n\u00EDm antidiabetik od monoterapie k dvojkombinac\u00EDm, trojkombinac\u00EDm i v\u00EDcekombinac\u00EDm l\u00E9k\u016F. Metformin z\u016Fst\u00E1v\u00E1 zat\u00EDm l\u00E9kem prvn\u00ED volby, pokud je sn\u00E1\u0161en a pokud nen\u00ED kontraindikov\u00E1n. V dal\u0161\u00EDm kroku m\u00E1me \u0161irokou mo\u017Enost volby nejm\u00E9n\u011B 5 skupin l\u00E9k\u016F. Nov\u00E9 algoritmy pou\u017E\u00EDvan\u00E9 ve Spojen\u00FDch st\u00E1tech zav\u00E1d\u011Bj\u00ED ur\u010Ditou preferenci inkretinov\u00E9 l\u00E9\u010Dby (gliptiny a inkretinov\u00E1 analoga) a nov\u00E9 skupiny gliflozin\u016F p\u0159ed tradi\u010Dn\u00EDmi postupy. Indikaci antidiabetik tak \u010Dekaj\u00ED v nejbli\u017E\u0161\u00EDch letech bu\u010F velk\u00E9 zm\u011Bny nebo minim\u00E1ln\u011B diskuse o preferenci jednotliv\u00FDch l\u00E9kov\u00FDch skupin v\u010Detn\u011B skupin v diabetologii nov\u00FDch."@cs . "23079" . "11110" . "V" . "Diabetes mellitus 2. typu l\u00E9\u010D\u00EDme dnes postupn\u00FDm p\u0159id\u00E1v\u00E1n\u00EDm antidiabetik od monoterapie k dvojkombinac\u00EDm, trojkombinac\u00EDm i v\u00EDcekombinac\u00EDm l\u00E9k\u016F. Metformin z\u016Fst\u00E1v\u00E1 zat\u00EDm l\u00E9kem prvn\u00ED volby, pokud je sn\u00E1\u0161en a pokud nen\u00ED kontraindikov\u00E1n. V dal\u0161\u00EDm kroku m\u00E1me \u0161irokou mo\u017Enost volby nejm\u00E9n\u011B 5 skupin l\u00E9k\u016F. Nov\u00E9 algoritmy pou\u017E\u00EDvan\u00E9 ve Spojen\u00FDch st\u00E1tech zav\u00E1d\u011Bj\u00ED ur\u010Ditou preferenci inkretinov\u00E9 l\u00E9\u010Dby (gliptiny a inkretinov\u00E1 analoga) a nov\u00E9 skupiny gliflozin\u016F p\u0159ed tradi\u010Dn\u00EDmi postupy. Indikaci antidiabetik tak \u010Dekaj\u00ED v nejbli\u017E\u0161\u00EDch letech bu\u010F velk\u00E9 zm\u011Bny nebo minim\u00E1ln\u011B diskuse o preferenci jednotliv\u00FDch l\u00E9kov\u00FDch skupin v\u010Detn\u011B skupin v diabetologii nov\u00FDch." . . "Sva\u010Dina, \u0160t\u011Bp\u00E1n" . . . . "type 2 diabetes mellitus; oral antidiabetics; metformin; incretin therapy; gliptins; gliflozins"@en . . . "Jak dnes indikujeme peror\u00E1ln\u00ED antidiabetika (od metforminu ke gliptin\u016Fm a gliflozin\u016Fm)"@cs . . . . "CZ - \u010Cesk\u00E1 republika" . "Jak dnes indikujeme peror\u00E1ln\u00ED antidiabetika (od metforminu ke gliptin\u016Fm a gliflozin\u016Fm)" . . "0042-773X" . "9" . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . "1"^^ . . "RIV/00216208:11110/14:10281251!RIV15-MSM-11110___" . "RIV/00216208:11110/14:10281251" . "Jak dnes indikujeme peror\u00E1ln\u00ED antidiabetika (od metforminu ke gliptin\u016Fm a gliflozin\u016Fm)"@cs . "http://www.prolekare.cz/linkout/49794" . "Today we treat Type 2 diabetes mellitus by gradually adding antidiabetics from monotherapy to double, triple and multi combinations of medicines. Metformin still remains the first-line medicine, if well tolerated and not contraindicated. In the next step, we have a wide choice of 5 groups of medicines at least. The new algorithms used in the U.S.A. introduce some degree of preference for the incretin therapy (gliptins and incretin analogues) and the new groups of gliflozins over the standard treatments. In the near future, the indication of antidiabetics is therefore about to undergo big changes or at least a discussion about the preferences of the individual groups of medicines including those new to diabetology."@en . "5"^^ . . . "1"^^ . . . "Jak dnes indikujeme peror\u00E1ln\u00ED antidiabetika (od metforminu ke gliptin\u016Fm a gliflozin\u016Fm)" . "How we indicate oral antidiabetics today (from metformin to gliptins and gliflozins)"@en . .